A Response to: “Letter to the Editor Regarding ‘Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis’” - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Clarification on the Letter Addressing the Indirect Comparison of Long-Term Efficacy Between Tralokinumab and Lebrikizumab in Moderate-to-Severe Atopic Dermatitis Patients

  • By

  • Matthias Augustin

  • April W. Armstrong

  • Naiem T. Issa

  • Anne Sohrt Petersen

  • Rie von Eyben

  • Teodora Festini

  • Tiago Torres

  • June 26, 2026

Share

Original Source(s)

A Response to: “Letter to the Editor Regarding ‘Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis’”

  • by Matthias Augustin, April W. Armstrong, Naiem T. Issa, Anne Sohrt Petersen, Rie von Eyben, Teodora Festini, Tiago Torres

  • June 26, 2026

Related Content

Atopic Dermatitis Treatment Targets Defined

Consensus definitions for disease control in atopic dermatitis aim to standardize clinical trial end points and support treat-to-target strategies.

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

Editorial: Type 2 inflammatory skin diseases: novel therapies and clinical insights